To help you bring attention to hemophilia and other inherited bleeding disorders in your local and global community this World Hemophilia Day, the WFH is offering free downloadable resources you can use to share the news with your friends, family, and your region.
Here’s a complete list of everything you can download to help you make an impact on April 17 this year. All content is available in English, French and Spanish. Most of these materials are available now.
- Poster
- Website banner
- Email signature graphic
- “How to get involved” one-pager
- “Light it up Red” sample letter
- Advocacy toolkit detailing more ways to get involved
- Government petition one-pager with sample letter
- Social media cover photos and graphics
- Zoom background
- And more!
The WFH is proud to include Instagram in our WFH celebration this year for the first time. We are offering graphic templates on our website to help you get the most out of this platform on April 17, so don’t forget to have a look!
World Hemophilia Day is just a few weeks away—but more resources coming soon! Stay tuned to hear about:
- The official launch of the World Hemophilia Day story site
- A social media toolkit with post examples
- The list of monuments Lighting it Up Red this year
Donate today and help create a brighter future for those affected by bleeding disorders
Join the fight for equal access to care for those living with hemophilia and other inherited bleeding disorders by showing your support on World Hemophilia Day. Your contribution will help fund the creation of free resources to bring these conditions to the attention of policymakers and raise awareness in the global community. Visit give.wfh.org to make a donation today.
To find out more about World Hemophilia Day, click here.
The WFH would like to thank our 2024 World Hemophilia Day sponsors for their continued support: Bayer, BioMarin Pharmaceutical Inc., Biotest, CSL Behring, F. Hoffman-La Roche Ltd., GC Pharma, Grifols, Kedrion, LFB S.A, Novo Nordisk, Octapharma, Pfizer, Sanofi, Sobi, Spark Therapeutics, and Takeda.